We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Real‐life intraclass switch among IL‐17 inhibitors in psoriasis: results from a single‐centre, 24‐week, retrospective study.
- Authors
Sotiriou, E.; Bakirtzi, K.; Papadimitriou, I.; Tsentemeidou, A.; Kougkas, N.; Panagopoulou, A.; Ioannides, D.; Vakirlis, E.
- Abstract
In our study, 3 patients (6.8%) experienced >=1 AE: 1 patient reported candidiasis infection while on secukinumab, and 2 injection-site reactions (1 patient on secukinumab and 1 on ixekizumab). Demographics and characteristics of first IL-17 non-responder patients and clinical outcomes after second IL-17 biologic treatment are presented in Table 1. We finally assessed the overall percentage of patients with previous exposure to IL-17 inhibitors obtaining an absolute PASI <= 3 at weeks 12 and 24 after second/third anti-IL-17 agent initiation.
- Subjects
INTERLEUKIN-17; PSORIASIS; PSORIATIC arthritis
- Publication
Journal of the European Academy of Dermatology & Venereology, 2022, Vol 36, Issue 11, pe952
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.18381